- Home
- JFU vs LTRN Comparison
JFU vs LTRN Comparison
Compare JFU & LTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JFU | LTRN |
|---|---|---|
| Founded | 2006 | 2013 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.9M | 27.6M |
| IPO Year | 2018 | 2020 |
Fundamental Metrics
Financial Performance| Metric | JFU | LTRN |
|---|---|---|
| Price | $3.02 | $0.81 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $17.50 |
| AVG Volume (30 Days) | 2.7K | ★ 279.3K |
| Earning Date | 12-09-2022 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.65 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4,000.66 | N/A |
| Revenue Next Year | $5.00 | N/A |
| P/E Ratio | $1.43 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.98 | $0.83 |
| 52 Week High | $9.48 | $4.58 |
Technical Indicators
Market Signals| Indicator | JFU | LTRN |
|---|---|---|
| Relative Strength Index (RSI) | 52.97 | 20.33 |
| Support Level | $1.99 | N/A |
| Resistance Level | $2.90 | $1.96 |
| Average True Range (ATR) | 0.14 | 0.14 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 54.19 | 6.56 |
Price Performance
Historical ComparisonAbout JFU 9F Inc.
9F Inc is a digital technology and wealth management service provider aiming to empower institutional partners with financial technologies as well as attract investors with investment opportunities that come with the vast potential of China's new consumer economy and the appreciation of world-wide assets and access to quality products at a competitive price. The Company's operations are organized into segments, consisting of E-commerce services, technology Empowerment service, and Wealth Management services.
About LTRN Lantern Pharma Inc.
Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform. The company utilizes its proprietary RADR platform to identify, develop, and advance small molecule therapies and antibody-drug conjugates, with a pipeline that includes three lead small molecule drug candidates (LP-300, LP-184, and LP-284) targeting solid tumors and blood cancers. It also advances programs through its subsidiary focused on central nervous system and brain cancers.